AI in fungal drug development: opportunities, challenges, and future outlook.

Journal: Frontiers in cellular and infection microbiology
Published Date:

Abstract

The application of artificial intelligence (AI) in fungal drug development offers innovative strategies to address the escalating threat of fungal infections and the challenge of antifungal resistance. This review evaluates the current landscape of fungal infections, highlights the limitations of existing antifungal therapies, and examines the transformative potential of AI in drug discovery and development. We specifically focus on how AI can enhance the identification of new antifungal agents and improve therapeutic strategies. Despite numerous opportunities for advancement, significant challenges remain, particularly regarding data quality, regulatory frameworks, and the complexities associated with the drug development process. This review aims to provide insights into recent advancements in AI technologies, their implications for the future of fungal drug development, and the necessary research directions to effectively leverage AI for improved patient outcomes.

Authors

  • Yanjian Li
    College of Life and Health Sciences, Northeastern University, Shenyang, China.
  • Yue Qiao
    College of Life and Health Sciences, Northeastern University, Shenyang, China.
  • Yuanyuan Ma
    Department of Gynecology, The Second People's Hospital of Shenzhen, Shenzhen, China.
  • Peng Xue
    National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen Ding
    Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, Jiangsu, China.